Post-marketing surveillance of albumin-bound paclitaxel for breast cancer.
Phase of Trial: Phase IV
Latest Information Update: 21 Feb 2013
At a glance
- Drugs Paclitaxel (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 21 Feb 2013 New trial record
- 14 Feb 2013 Results from this post-marketing surveillance have been reported in a Taiho Pharmaceutical media release. These findings were sufficient to support the lifting of a previous condition for approval of Abraxane set forth by the Japanese regulatory body.